A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 25,903 followers.

A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma #lymphoma #lymsm https://t.co/YPj2YxpgvD

28 Nov 2022

Reply Repost Favourite

A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma https://t.co/nKTJLCLDoY https://t.co/fDjf7ins5n

12 Nov 2022

Reply Repost Favourite

"#3: A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma 👩‍⚕️👨‍⚕️ Yuan Chen et al Read now 👉 https://t.co/zwsjVp2FMf #Lymphoma #CellTherapy #Oncol

11 Nov 2022

Reply Repost Favourite

New research: A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma: Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous… https://t.co/ie

11 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.